Form 4: Hyperfine CEO Maria Sainz Awarded Stock Options

Maria Sainz, President and CEO of Hyperfine, Inc., was granted stock options for 1,435,000 shares of Class A Common Stock on March 28, 2024.

Summary

• On March 28, 2024, Maria Sainz, the President and CEO of Hyperfine, Inc., was granted stock options to purchase 1,435,000 shares of Class A Common Stock.
• The options vest as to 25% on March 28, 2025, and the remaining 75% vests in 36 equal monthly installments thereafter.
• Vesting is contingent upon Ms. Sainz's continued service with the company through each applicable vesting date.
• The options expire on March 28, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the CEO's ability to lead the company. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The value of the stock options is dependent on the future performance of Hyperfine's stock price.
• If Ms. Sainz leaves the company before the options are fully vested, she will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the stock option grant suggests an expectation of future growth and value creation.

Industry Context

Stock option grants are a common practice in the technology and healthcare industries to attract, retain, and incentivize key executives. The size and vesting schedule of the grant are typical for a CEO of a company like Hyperfine.

Comparison to Industry Standards

• Stock option grants for CEOs in similar-sized medical device companies typically range from 1% to 5% of outstanding shares.
• Vesting schedules are also standard, with many companies using a four-year vesting period with a one-year cliff.
• Companies like Butterfly Network and Nano-X Imaging, which are also in the medical imaging space, have used similar compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the CEO's interests with theirs.
• Employees may see it as a sign of confidence in the company's future.
• The grant has no immediate impact on customers, suppliers, or creditors.

Key Dates